Compounds > ono 6818
Page last updated: 2024-11-08

ono 6818

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ONO 6818: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID216294
CHEMBL ID25892
SCHEMBL ID6748609
MeSH IDM0377513

Synonyms (29)

Synonym
208848-19-5
freselestat
ono-6818
ono 6818
2-(5-amino-6-oxo-2-phenylpyrimidin-1(6h)-yl)-n-(1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl)acetamide
bdbm50095522
2-(5-amino-6-oxo-2-phenyl-6h-pyrimidin-1-yl)-n-[1-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-2-methyl-propyl]-acetamide
CHEMBL25892 ,
2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide
1(6h)-pyrimidineacetamide, 5-amino-n-(1-((5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl)carbonyl)-2-methylpropyl)-6-oxo-2-phenyl-
ono-po 736
freselestat [inn]
2-(5-amino-6-oxo-2-phenylpyrimidin-1(6h)-yl)-n-((1rs)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl)acetamide
unii-1cw4rl23vp
1cw4rl23vp ,
(rs)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-ylcarbonyl)-2-methylpropyl]-2-(6-oxo-2-phenyl-5-amino-1,6-dihydropyrimidin-1-yl)acetamide
YSIHYROEMJSOAS-UHFFFAOYSA-N
SCHEMBL6748609
AKOS027338660
5-amino-n-[1-[[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]-6-oxo-2-phenyl-1(6h)-pyrimidineacetamide
HY-15652
CS-0007925
ono6818
2-(5-amino-6-oxo-2-phenyl-1,6-dihydropyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide
2-(5-amino-6-oxo-2-phenylpyrimidin-1(6h)-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]ethanimidic acid
DTXSID50943150
ono-6818;ono-po-736;ono6818;ono 6818
2-(5-amino-6-oxo-2-phenylpyrimidin-1(6h)-yl)-n-(1-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl)acetamide
1(6h)-pyrimidineacetamide, 5-amino-n-[1-[[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-methylpropyl]-6-oxo-2-phenyl-

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095]."( ONO-6818 Cortech/Ono.
Trifilieff, A, 2002)		0.31
" For example, 6e is an orally active inhibitor of human neutrophil elastase that entered human clinical studies, 52h is an orally bioavailable inhibitor of human chymase, and 82m is a FAAH inhibitor with in vivo endocannabinoid-enhancing activity."( Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
Costanzo, MJ; Maryanoff, BE, 2008)		0.35

Dosage Studied

ExcerptRelevanceReference
" Finally, AZD9668 prevented airspace enlargement and small airway wall remodeling in guinea pigs in response to chronic tobacco smoke exposure whether dosed therapeutically or prophylactically."( AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase.
Churg, A; Ekholm, K; Falk-Håkansson, H; Gränse, M; Jungar, C; Kozma, V; Lal, H; Lindahl, M; Ottosson, T; Sanfridson, A; Stevens, T; Wright, JL, 2011)		0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neutrophil elastaseHomo sapiens (human)Ki0.01210.00201.28669.5499AID1248076; AID321181; AID66805; AID91007
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID12450Half life after administering orally a dose of 3 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID321186Half life in rat at 3 mg/kg, po2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
AID321185Efficacy in po dosed hamster acute lung injury model2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
AID10865Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12454Half life after the administered orally a dose of 1 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID321181Inhibition of human neutrophil elastase2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
AID10867Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID84849Inhibition of HNE-induced lung hemorrhage in hamsters after oral administration followed by intratracheal instillation of HNE (10 U/lung)2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID11786Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID13655Percent oral bioavailability evaluated in rat2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.
AID228897Effective dose determined in an animal model which lasted for more than 8 h2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.
AID1248081Selectivity ratio of IC50 for human PR3 to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.
AID29818Percent oral bioavailability evaluated in dog2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.
AID10869Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID1248087Selectivity ratio of IC50 for human trypsin to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.
AID10866Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12513Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID11790Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID10868Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID66805Binding constant derived from inhibition of elastase catalyzed hydrolysis of synthetic substrate2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID9137Bioavailability was evaluated after oral administration in dog2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12516Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID91007Inhibition of human neutrophil elastase HNE, hydrolysis of MeO-Suc-Ala-Ala-Pro-Val-pNa2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12512Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID321188Tmax in rat at 3 mg/kg, po2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
AID1248083Selectivity ratio of IC50 for human CatG to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.
AID12514Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12515Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID1248084Selectivity ratio of IC50 for human chymotrypsin to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.
AID321187Cmax in rat at 3 mg/kg, po2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
AID1248086Selectivity ratio of IC50 for porcine pancreatic elastase to IC50 for human neutrophil elastase2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.
AID24968Percent oral bioavailability evaluated in monkey2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.
AID147548Effective dose was determined for inhibition of HNE-induced lung hemorrhage in hamster after oral administration prepared as a suspension in 0.5% CMC2000Journal of medicinal chemistry, Dec-28, Volume: 43, Issue:26
Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase.
AID321189Oral bioavailability in rat at 3 mg/kg2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
AID11787Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID1248076Inhibition of human neutrophil elastase2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.
AID12326Half life after administering orally a dose of 10 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID13167Bioavailability was evaluated when a dose of 3 mg/kg was administered orally2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12511Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12327Half life after administering orally a dose of 30 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID11788Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID13168Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID11789Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12451Half life after administering orally a dose of 3 mg/kg to a fasting rat2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID7348Bioavailability was evaluated after oral administration in monkey2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
AID12452Half life after administering intravenously a dose of 1 mg/kg2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (83.33)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.71 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetic acid
Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.		2.0210monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
glycine
[no description available]		2.0610alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		210chromones
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		2.021011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
trinitrobenzenesulfonic acid
Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.		2.0210arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
midesteine
midesteine: a cyclic thiolic neutrophil elastase inhibitor		3.2110
sivelestat
sivelestat: inhibitor of neutrophil elastase; structure given in first source		2.0610N-acylglycine;
pivalate ester
efegatran
efegatran: RN & structure given in first source; RN given refers to parent cpd (D)-isomer		3.1410
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		210macrolide lactambacterial metabolite;
immunosuppressive agent
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		210
benzoyl-norleucyl-lysyl-arginyl-arginal
[no description available]		3.1410
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.0210aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
CAY10435
[no description available]		3.1410oxazolopyridine
ol-135
[no description available]		3.1410
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		4.7290
compstatin
compstatin: binds to complement 3; amino acid sequence in first source		3.1410
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.0110
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide
N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide: structure in first source		3.5920
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		4.7290
ConditionIndicatedRelationship StrengthStudiesTrials
Bleeding
[description not available]		0210
Disease, Pulmonary
[description not available]		03.3620
Hemorrhage
Bleeding or escape of blood from a vessel.		0210
Lung Diseases
Pathological processes involving any part of the LUNG.		03.3620
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		03.0310
Lung Injury, Acute
[description not available]		02.0610
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		02.0610
Emphysema
A pathological accumulation of air in tissues or organs.		02.4420
Pneumonia
Infection of the lung often accompanied by inflammation.		02.0610
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		02.0610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.730
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.4220
Eczema, Atopic
[description not available]		0210
Anasarca
[description not available]		0210
Allergic Reaction
[description not available]		0210
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		0210
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		0210
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		0210